Is the obesity drug market still a duopoly?
Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...
Ozempic maker says its Australian market could be half the population
Novo Nordisk says many Australians would be willing to pay the out-of-pocket costs for its blockbuster medicines, which can ...
Investing.com Australia6d
GLP1 Tracker: Lilly continues to outgrow Novo- analyst
Bernstein analysts told investors in a note Tuesday that Eli Lilly (NYSE: LLY) is gaining ground in the GLP-1 market, edging ...
Investing.com Australia13d
Lilly unveils higher vial doses of obesity drug that are cheaper than injector pen
Investing.com - Eli Lilly (NYSE:LLY) announced on Tuesday that it would begin selling 7.5 milligram and 10 milligram single-dose vials of its Zepbound weight-loss drug at a roughly $150 discount to ...
Channel 300014d
Patients struggle with lack of consistent coverage for popular weight-loss drugs
Many employers and insurers are scaling back coverage of Wegovy and Zepbound and a key government program, Medicare, doesn’t cover the drugs for obesity. Meanwhile, some big employers are adding ...
NBC New York14d
Yearslong shortage of popular weight-loss and diabetes drugs resolved, FDA says
In December, the agency said the same thing when it declared that shortages had ended for Eli Lilly and Co.'s Zepbound and Mounjaro. Zepbound is approved to treat obesity and Mounjaro is approved ...